<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872140</url>
  </required_header>
  <id_info>
    <org_study_id>1207</org_study_id>
    <nct_id>NCT04872140</nct_id>
  </id_info>
  <brief_title>Effect of Iron-fortified Pea Powder on Exercise Performance</brief_title>
  <official_title>Effect of Low-phytate Pea Powder With High Iron Bioavailability on Iron Status of Female Runners</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female endurance athletes are susceptible to iron deficiency and this can impact their&#xD;
      exercise performance. This study assesses the impact of an pea protein supplement with high&#xD;
      iron bio-availability on iron status and exercise performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female endurance athletes are susceptible to iron deficiency due to poor iron intake from&#xD;
      diets or possibly because of destruction of red blood cells during foot-strike hemolysis.&#xD;
      This study will evaluate the impact of 8-weeks of iron supplementation through consumption of&#xD;
      a pea-protein power that has high iron bio-availability due to low phytate levels. This will&#xD;
      be compared to consumption of regular iron protein powder and maltodextrin placebo by&#xD;
      randomizing participants to three groups. Participants will be assessed at baseline and after&#xD;
      8 weeks of supplementation for exercise performance (maximal aerobic capacity and a 5 km time&#xD;
      trial running test), blood levels of ferritin and hemoglobin, and body composition (fat mass&#xD;
      and lean tissue mass).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are being randomized to three groups for the 8-week intervention:&#xD;
Pea power with high iron bio-availability&#xD;
Regular pea powder&#xD;
Placebo (maltodextrin)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The powder supplements are being administered in a blinded manner. An individual who is separate from the rest of the research team will generate the allocation schedule and prepare the supplement packages so that participants, investigators, and outcome assessors are blinded. Statistical analysis will be blinded by coding of groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ferritin levels</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>blood ferritin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximal aerobic capacity</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Maximal aerobic capacity (mL/kg/min) measured on a treadmill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in exercise time trial performance</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Time (minutes) to complete 5 km running on a treadmill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin levels</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Blood hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lean tissue mass</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Lean tissue mass (kg) measured with dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fat mass</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Fat mass (kg) measured with dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Pea power with high iron bio-availability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pea powder with low phytate levels to increase iron bio-availability (7mg iron per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pea powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pea powder with normal phytate levels (7mg iron per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (maltodextrin) powder (0g iron per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low phytate pea powder</intervention_name>
    <description>Exercise performance with low phytate pea powder</description>
    <arm_group_label>Pea power with high iron bio-availability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Regular pea powder</intervention_name>
    <description>Exercise performance with regular pea powder</description>
    <arm_group_label>Pea powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (maltodextrin)</intervention_name>
    <description>Exercise performance with placebo (maltodextrin)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Regularly participate in aerobic endurance training&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contra-indications to exercise testing as determined with the &quot;Get Active&#xD;
             Questionnaire&quot;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Chilibeck, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Chilibeck, PhD</last_name>
    <phone>1-306-343-6577</phone>
    <email>phil.chilibeck@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N5B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Chilibeck, PhD</last_name>
      <phone>1-306-343-6577</phone>
      <email>phil.chilibeck@usask.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>May 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Phil Chilibeck</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

